首頁 > 市場調查報告書 > 製藥

重組 DNA 技術市場：按產品類型、應用、地區 - 規模、份額、前景、機會分析，2022-2030

市場調查報告書

商品編碼

1110089

重組 DNA 技術市場：按產品類型、應用、地區 - 規模、份額、前景、機會分析，2022-2030

Recombinant DNA Technology Market, by Product Type, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月07日 | 出版商:

Coherent Market Insights | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

重組 DNA (rDNA) 技術是一項新技術，它在藥物開發、農業和研究等許多領域取得了進展。重組 DNA 技術引入了一類新的生物，稱為轉基因生物 (GMO) 或轉基因生物 (LMO)。我們已成功開發轉基因作物（BT 棉花）、克隆動物、生物農藥、生物燃料和基因療法。 RDNA技術刺激了生物製藥行業向CAR-T細胞治療、雙特異性和單克隆抗體等多種rDNA產品的開發，從而推動了重組DNA技術市場的增長。此外，基因編輯系統CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）在穩定和增強免疫力方面發揮著重要作用，在疫苗和藥物開發方面具有巨大潛力。

市場動態

預計聯盟等無機戰略的日益採用將在預測期內推動市場增長。例如，2020 年 9 月，國家生物技術信息中心發布的數據顯示，總部位於印度的生物技術和生物製藥公司 Serum Institute of India Pvt, Ltd. (SII) 和衛生部下屬的城市研究醫學研究委員會 (ICMR) 已合作進行兩種全球候選疫苗的臨床開發。第一個是ChAdOx1-S，一種由牛津大學/阿斯利康開發的非複制型病毒載體疫苗。該疫苗正在巴西進行 III 期臨床試驗。 ICMR 已在 14 個臨床試驗地點啟動 II/III 期橋接研究。 ICMR-國家結核病研究所 (NIRT)（欽奈）是牽頭機構。

此外，2020年9月，ICMR和Serum Institute of India Pvt.我們也在合作進行單位納米顆粒佐劑疫苗的臨床開發，我們計劃在疫苗由SII生產後於2020年10月下旬開始臨床試驗.該試驗由印度浦那的 ICMR-國家愛滋病研究所 (NARI) 領導。

本研究的主要特點

本報告深入分析了以 2021 年為基準年的預測期（2022-2030 年）的全球重組 DNA 技術市場、市場規模和復合年增長率 (CAGR%)。
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球重組 DNA 技術市場主要參與者的概況。
本次調查涵蓋的主要公司包括 Thermo Fisher Scientific, Inc.、Biogen, Inc.、Sanofi Pasteur、Merck & Co., Inc.、Pfizer, Inc.、Profacgen、Amgen, Inc. 和 Monsanto Company
本報告中的見解將使營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
《全球重組 DNA 技術市場》報告面向行業內的各種利益相關者，包括投資者和供應商、產品製造商、分銷商、新進入者和金融分析師。
利用用於分析全球重組 DNA 技術市場的各種戰略矩陣促進利益相關方的決策。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第2章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 按產品類型劃分的市場概況
- 市場快照：按應用
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、監管和趨勢分析

市場動態
- 驅動程序
- 限制因素
- 市場機會
監管場景
主要亮點
PEST 分析
流行病學
影響分析
對PORTER的分析

第 4 章重組 DNA 技術的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章全球重組 DNA 技術市場：按產品類型，2017-2030 年

重組蛋白藥物
胰島素
人類生長激素
促紅細胞生成素
干擾素
凝血因子
集落刺激因子
融合蛋白
其他
疫苗
轉基因作物
表達系統
原核細胞
哺乳動物細胞
酵母
昆蟲
其他
細胞和基因治療
基因編輯

第 6 章。全球重組 DNA 技術市場，按應用分列，2017-2030 年

治療區
農業領域
調查

第 7 章。2017-2030 年全球重組 DNA 技術市場，按地區分列

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東地區
非洲
北非
中非
南非

第 8 章競爭格局

熱圖分析
公司簡介
- Thermo Fisher Scientific, Inc.
- 百健公司
- 賽諾菲巴斯德
財務摘要
- 默克公司
財務摘要
- 輝瑞公司
財務摘要
- Profacgen
財務摘要
- 安進公司
財務摘要
- 孟山都公司
財務摘要

第9章章節

參考資料
研究方法介紹
關於出版商

簡介目錄

Product Code: CMI893

Recombinant DNA (rDNA) technology is a novel technique that has led to advances in a number of different fields such as drug development, agriculture, and research. Recombinant DNA technology has introduced new classes of organisms namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, and gene therapy successfully. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA products such as CAR-T cell therapy and bispecific and monoclonal antibodies, in turn, favoring the growth of the recombinant DNA technology market. Moreover, the gene-editing system -Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) - holds great potential for the development of vaccines and drugs, as it plays a major role in the stability and enhancement of immunity.

Market Dynamics

The increasing adoption of inorganic strategies such as partnership is expected to drive the market growth over the forecast period. For instance, in September 2020, according to the data published by the National Center for Biotechnology Information, Serum Institute of India Pvt., Ltd. (SII), a biotechnology and Biopharmaceutical Company based in India, and the Indian Council of Medical Research (ICMR), an autonomous organization under the Department of Health Research, partnered for the clinical development of two global vaccine candidates. The first one is ChAdOx1-S, which is a non-replicating viral vector vaccine developed by the University of Oxford/AstraZeneca. This vaccine is undergoing phase III clinical trials in Brazil. Phase II/III bridging studies have been initiated by ICMR at 14 clinical trial sites. ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai is the lead institution.

Moreover, in September 2020, ICMR and Serum Institute of India Pvt., Ltd. (SII) have also partnered for the clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine, developed by Novavax, Inc., biotechnology company that develops vaccines to counter serious infectious diseases from the U.S. The trial will be initiated in the second half of October 2020 after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune, India.

Key features of the study:

This report provides an in-depth analysis of the global recombinant DNA technology market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant DNA technology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant DNA technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant DNA technology market

Detailed Segmentation:

Global Recombinant DNA Technology Market, By Product Type:
- Recombinant Protein Drugs
  - Insulin
  - Human Growth Hormone
  - Erythropoietin
  - Interferon
  - Blood Factors
  - Colony Stimulating Factors
  - Fusion Proteins
  - Others
- Vaccines
- Genetically Modified Crops
- Expression Systems
  - Prokaryotic Cells
  - Mammalian Cells
  - Yeats
  - Insect
  - Others
- Cell and Gene Therapy
- Gene Editing
Global Recombinant DNA Technology Market, By Application:
- Therapeutics
- Agriculture
- Research
Global Recombinant DNA Technology Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Thermo Fisher Scientific, Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biogen, Inc.
- Sanofi Pasteur
- Merck & Co., Inc.
- Pfizer, Inc.
- Profacgen
- Amgen, Inc.
- Monsanto Company

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
PEST Analysis
Epidemiology
Impact Analysis
PORTER's Analysis

4. Global Recombinant DNA Technology Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Recombinant DNA Technology Market, By Product Type, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Recombinant Protein Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Genetically Modified Crops
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Expression Systems
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Gene Editing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Recombinant DNA Technology Market, By Application, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Therapeutics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Agriculture
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Research
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Recombinant DNA Technology Market, By Region, 2017 - 2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
North Africa
Central Africa
South Africa